Rigel Pharmaceuticals (NASDAQ:RIGL) does about 1.14M shares in volume on a normal day but saw 1409770 shares change hands in Friday trading. The company now has a market cap of 226.24M USD. Its current market price is $1.29, marking no change compared to the previous close of $1.29. The 52 week high reached by this stock is $1.96 whilst the lowest price level in 52 weeks is $0.71.
Rigel Pharmaceuticals (RIGL) has a 20-day trading average at $1.4060 and the current price is -34.18% off the 52-week high compared with 81.18% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.3386 and its 200-day simple moving average is $1.2049. If we look at the stock’s price movements over the week, volatility stands at 8.76%, which decreases to 6.68% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 41.09 to suggest the stock is neutral.
The consensus objective for the share price is $4.57, suggesting that the stock has a potential upside of 71.77% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 03, 2023 when Piper Sandler resumed the stock to “Neutral” and issued a price target of $2. Piper Sandler downgraded its price target at $7-$1.
Rigel Pharmaceuticals (RIGL) stock is down -12.84% over the week and -17.31% over the past month. Its price is -11.03% year-to-date and 5.74% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/30/2023, with the company’s earnings per share (EPS) of $0 above consensus estimates by $0.03. RIGL’s earnings per share are forecast to grow by 57.10% this year and 250.00% over next year. Expected sales for next quarter are $33.1 million, which analysts say will come at $148.99 million for the current fiscal year and next year at $192.17 million. In addition, estimates put the company’s current quarterly revenue at an average of $31.28 million.
To reach the target analysts have set, the stock logically needs to grow 71.77 percent from here.
Outstanding shares total 174.83M with insiders holding 2.06% of the shares and institutional holders owning 61.46% of the company’s common stock. The company has a return on investment of -104.48%. The forward price to earnings ratio is 15.08. The beta has a value of 1.00. Price to sales ratio is 1.94.
